BAT Launches Virtual R&D Visitor Experience

Apr.07.2022
BAT Launches Virtual R&D Visitor Experience
BAT launches virtual visitor experience showcasing cutting-edge research and development activities in various scientific fields.

January 19, 2022

 

BAT has launched a new virtual visitor experience that allows guests to "walk through" the company's research and development laboratories, meet top scientists, and view the results of new research. Tourists have the opportunity to explore the company's scientific methods and progress in reducing tobacco harm, as well as showcasing R&D activities in important and emerging fields such as biology, chemistry, toxicology, sensory science, aerosol analysis, product safety, consumer insights, and plant biotechnology. This underscores BAT's commitment to science in reducing the impact of its business on health and providing a better tomorrow. TMBAT has created a virtual R&D visitor experience, an online tour of its global R&D center located in Southampton, UK, allowing people to explore its cutting-edge science and innovation.

 

Experience is built on a foundation of the best available technology, open and transparent scientific methods, which support the reduction of risk in product portfolios and beyond nicotine activities. The company regularly welcomes visitors to its global research center, with over 3,500 people seeing the facilities firsthand since 2011. However, with travel greatly reduced, virtual experiences allow people from around the world to access and understand BAT's scientific research, reduce tobacco harm reduction (THR) activities, and gain insights and perspectives from experts.

 

David O'Reilly, PhD, the Director of scientific research at BAT, emphasized the importance of research and development as the foundation of their work. By prioritizing science and research, they have made significant progress in developing new product categories that have undergone rigorous testing and scientific validation as reduced-risk alternatives to traditional tobacco products. Their research is heavily influenced by consumer preferences and continually incorporates evolving scientific and innovative developments into their products. This approach allows them to offer a range of enjoyable, reduced-risk alternatives to cigarettes while maintaining very high safety and quality standards.

 

Our new virtual visitor experience showcases the breadth of science we are conducting and the strong scientific framework we are using to evaluate and support our products in reducing tobacco harm.

 

A virtual visitor experience has been developed, offering a one-stop center for people who wish to learn about the science behind BAT. This includes a tour through the 360-degree lab, animations, videos, scientist profiles and podcasts. The aim of this initiative is to highlight BAT's commitment in building a better future while reducing its impact on public health. BAT invests nearly £350 million annually to find innovative ways to reduce its influence on public health and aims to have 50 million non-combustible product consumers by 2030.

 

BAT conducts research in a wide range of scientific fields including molecular biology, toxicology, and chemistry, driving constant innovation and learning, and establishing the company as an industry leader.

 

Visitors who take a tour of the research and development virtual experience will be able to explore:

 

Sensory Science: This specialized department helps BAT better understand consumer product experiences and decodes them into actionable insights to support product and brand development. Biotech Laboratory: BAT scientists utilize their specialized knowledge in whole-genome sequencing, metabolomics, and computational biology to provide enhanced consumer experiences. These teams also grow plants and identify sustainable compound sources. Biology Laboratory: Scientists test BAT's new category products for potential impacts on human cells compared to cigarette smoke. Battery Laboratory: The facility revolutionizes the design, development, and testing of BAT's rechargeable devices. The batteries undergo rigorous speed tests to ensure they meet high-quality standards.

 

Original link:

 

British American Tobacco (BAT) has launched a virtual research and development visitor experience, showcasing world-class science behind their next-generation reduced-risk† nicotine products.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18